Core Insights - Nautilus Biotechnology, Inc. has successfully deployed its first external field evaluation unit at the Buck Institute, generating tau proteoform data that validates its single-molecule proteomics platform [1][2][4] - The collaboration aims to explore tau proteoforms' role in neurodegeneration and cognitive decline, with initial findings to be presented at the 2025 HUPO World Congress [3][6] - The instrument's performance demonstrates high reproducibility and readiness for broader research applications, particularly in studying Alzheimer's disease [4][5] Company Overview - Nautilus is a development stage life sciences company focused on creating a platform for quantifying and understanding the complexity of the proteome [7][8] - The company's mission is to democratize access to proteomics, enabling advancements in human health and medicine [8] Research Collaboration - The ongoing collaboration with the Buck Institute leverages Nautilus' Proteome Analysis Platform to investigate the functional variants of tau protein associated with Alzheimer's disease [3][5] - The joint efforts have shown that the tau assay can generate reproducible data across different research settings, establishing a foundation for future studies [4][5]